Syngene International Limited has informed the Exchange regarding a press release dated July 23, 2025, titled "First quarter revenue from operations up 11% year-on-year to Rs. 875 Cr".
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syngene International reported Q1 FY26 revenue from operations of Rs. 875 Cr, up 11% year-on-year from Rs. 790 Cr in Q1 FY25. Reported EBITDA grew 19% to Rs. 224 Cr, with EBITDA margin expanding by about 200 basis points to 25%. Profit after tax (before exceptional items) jumped 59% to Rs. 87 Cr, with PAT margin improving to 10% from 7%, partly aided by a tax benefit from transfer of gratuity funds to an Employee Gratuity Trust. The company highlighted strong growth in Research Services driven by conversion of pilot programs into long-term contracts, and progress at its new Biologics Unit III facility in Bengaluru, with the U.S. Bayview facility expected to start operations later this year. The company reaffirmed its full-year guidance and noted a clean USFDA inspection of its Human Pharmacology Unit with no observations.
Positive quarter with broad-based growth across revenue, margins, and profits signals strong operational momentum and likely supports the stock. Margin expansion and reaffirmed FY26 guidance are key positives for shareholders.